#54„´™Ÿ ™·àV 3“Z

Size: px

Start display at page:

Download "#54„´™Ÿ ™·àV 3“Z"

あかりみのしま
5 years ago
Views:

1 A allograft, Fis BN, non-immunosuppression B isograft, BN BN, non-immunosuppression C allograft, Fis BN, immunosuppression, 1.0 mg/kg/day of FK-506 control normal Fis 1 14 A B C A TUNEL 5 7 B C A Fas A recipient Fas FasL FasL Fas/FasL Fas 1 necrosis 1 Kerr 2 apoptosis 3 10 Fas/FasL 11 TNF 12 granzymes 13 lymphotoxin Fas/FasL T T CTL AIDS Fas/FasL 2 1 Major-mismatch Fischer Fis RT1 lv1 donor

2 106 Brown-Norway BN RT1 recipient g Kanagawa Japan microsurgery 2.0 ml/kg a donor b recipient c recipient donor recipient donor recipient A B C 42 control 10 A Fis BN allograft B BN isograft C Fis BN FK mg/kg/day allograft control Fis 3 a EDTA 7 2 µm hematoxylin-eosin HE b TUNEL TdT-mediated dutp-biotin nick end labeling 17 2 µm TUNEL 1,000 TUNEL apoptotic index AI TUNEL TUNEL c Fas 18 FasL 19 Santa Cruz Biotechnology, California, USA Fas FasL Bcl-2 20 Bcl-2

3 Control Fig. 1a allograft A 7 14 Fig. 1b, b, c B C Fig. 1. HE 100 b' 200 a b A 7 c A 14

4 108 Fig. 1. HE 100 b' 200 d B 7 e B 14 f C 7 g C 14 A 7 foamy cell b' 14 empty lacunae B C

5 109 Fig. 1d g 2 Control Fig. 2a A Fig. 2b d B C Fig. 2. TUNEL 200 a b A 1 c A 3 d A 14 TUNEL A 1 b 3 c

6 110 Fig. 2. TUNEL 200 e apoptotic index TUNEL ,000 TUNEL A B C *P < 0.01 f apoptotic index TUNEL A B C *P 0.01 A AI B C P 0.01 Fig. 2e, f 3 Control TUNEL A 7 A 7 Fig. 3a,b 4 2 TUNEL Fas FasL Bcl-2 Fas FasL A B C 3 Fas 10 Fig. 4a f 3 A B C

111 Fig. 3. bar = 1 µm a, b A 7 2.0 1.6 10 A 11.0 4.5 B 8.4 3.0 C 9.4 3.2 Fig. 4g FasL A recipient Fig.

7 111 Fig. 3. bar = 1 µm a, b A A B C Fig. 4g FasL A recipient Fig. 5 B C Bcl-2 control A B C 10 Bcl-2 4 DNA Gavrieli TUNEL 17 TUNEL DNA DNA 3 -OH biotin dutp TdT 3 -OH DNA TUNEL 21 TUNEL control Fas FasL A B C 3 10 Fas A B C FasL A 10

8 112 Fig. 4. Fas 200 a A 3 b A 10 c B 3 d B 10 e C 3 f C 10 Fas g Fas ,000 Fas

9 113 Fig. 5. FasL 200 A 10 donor recipient FasL Fas/FasL Fas TNF 22 FasL Fas FasL 278 TNF matrix-metalloproteinase FasL FasL FasL host FasL Fas/FasL FasL Fas/FasL Fas A AI 61 Fas 1 Fas/FasL TNF-α nitric oxide NO 26

10 114 Bcl-2 Bcl Bcl-2 control A B C 10 Bcl-2 Bcl-2 Krams 1 7 AI 7 AI isograft allograft Matsuno 1 AI A AI AI TUNEL TUNEL AI 1 AI AI AI 5 1 allograft TUNEL control Fas Fas FasL recipient FasL Fas/FasL 3 Bcl-2 Bcl-2 4 AI 1 AI 1) Henkart PA: Mechanism of lymphocyte-mediated cytotoxicity. Annu Rev Immunol, 3: 31 58, ) Kerr JFR, Wyllie AH, Currie AR: Apoptosis: A basic biological phenomenon with wideranging implications in tissue kinetics. Brit J Cancer, 26: , ) Chikaraishi T, Ishikura H, Seki T, Koyanagi T, Yoshiki T: DNA nick end labeling of rat renal allografts treated with 15-deoxyspergualin DSG Transplant Proc, 27: , ) Matsuno T, Nakagawa K, Sasaki H, Ishine N, Inagaki M, et al.: Apoptosis in acute tubular necrosis

11 115 and acute renal allograft rejection. Transplant Proc, 26: , ) Ito H, Kasagi N, Shomori K, Osaki M, Adachi H: Apoptosis in the human allografted kidney. Transplantation, 60: , ) Matsuno T, Sasaki H, Ishido N, Nakagawa K, Ishikawa T, et al.: Apoptosis in human kidney allografts. Transplant Proc, 28: , ) Krams SM, Egawa H, Ouinn MB, Villanueva JC, Garcia-Kennedy R, et al.: Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation, 59: , ) Nawaz S, Fennell RH: Apoptosis of bile duct epithelial cells in hepatic allograft rejection. Histopathology, 25: , ) Afford SC, Hubscher S, Strain AJ, Adams DH, Neuberger JM: Apoptosis in the human liver during allograft rejection and end-stage liver disease. J Pathol, 176: , ) Dong C, Wilson JE, Winters GL, McManus BM: Human transplant coronary artery disease: pathological evidence for Fas-mediated apoptotic cytoxicity in allograft arteriopathy. Lab Invest, 74: , ) Nagata S, Golstein P: The Fas death factor. Science, 267: , ) Ratner A, Clark WR: Role of TNF-alpha in CD8+ cytotoxic T lymphocyte-mediated lysis. J Immunol, 150: , ) Shresta S, Heusel JW, Macivor DM, Wesselschmidt RL, Russell JH, et al.: Granzyme B plays a critical role in cytotoxic lymphocyteinduced apoptosis. Immunol Rev, 146: , ) Wang J, Nonomura N, Ichimaru N, Azuma H, Hatori M, et al.: Expression of Fas and Fas ligand in renal grafts with acute and chronic rejection in the rat model. J Interferon Cytokine Res, 17: , ) Kato S, Akasaka Y, Kawamura S: Fas antigen expression and its relationship with apoptosis in transplanted kidney. Pathol Int, 47: , ) Watanabe H, Nagasawa K, Hamada Y, Toshima T, Sakano Y, et al.: The significance of tumor necrosis factor TNF levels for rejection of joint-allograft. J Reconstr Micro Surg, 13: , ) Gavrieli Y, Sherman Y, Ben-Sasson SA: Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol, 119: , ) Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med, 169: , ) Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell, 75: , ) Tsujimoto Y, Cossman J, Jaffe E, Croce CM: Involvement of the bcl-2 gene in human follicular lymphoma. Science, 228: , ) , ) Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, et al.: The polypeptide encoded by the cdna for human cell surface antigen Fas can mediate apoptosis. Cell, 66: , ) Hanabuchi S, Koyanagi M: Fas and its ligand in a general mechanism of T cell mediated cytotoxicity. Proc Natl Acad Sci, 91: , ) Tanaka M, Suda T, Takahashi T, Nagata S: Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J, 14: , ) Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, et al.: Metalloproteinase-mediated release of human Fas ligand. J Exp Med, 182: , ) Blanco FJ, Ochs RL, Schwartz H, Lortz M: Chondrocyte apoptosis induced by nitric oxide. Am J Pathol, 146: 75 85, ) Nakopoulou L, Stefananki K, Papadakis J, Boletis J, Zeis PM, et al.: Expression of bcl-2 oncoprotein in various types of glomerulonephritis and renal allografts. Nephrol Dial Transplant, 11: , 1996.

北陸地域アイソトープ研究会誌第７号

北陸地域アイソトープ研究会誌第７号 IMRT Hyper-radiosensitivity and Increased radioresistance Radiation adaptive response Radiation-induced bystander effect 0.5 Gy hyper-radiosennsitivity HRS 0.5 Gy increased radioresistance IRR HRS IRR